The Food and Drug Administration has recently declared, due to the coronavirus, they are restricted on the ability to carry out inspections on Chinese medical products; however, they will use their further tools to examine product safety. In addition, risk-based checks in other parts of the globe will continue to be prioritised, to monitor the global drug supply chain. Furthermore, they stated that imported products are not posing any risk of an outbreak to the public.
“The Food and Drug Administration has recently declared, due to the coronavirus, they are restricted on the ability to carry out inspections on Chinese medical products.“
The FDA said in a statement: “It is important to reiterate that inspections are one of many tools that the agency uses to inform our risk strategy for imported FDA regulated products and to help prevent products that do not meet the FDA’s standards from entering the US market. A wide variety of FDA regulated products are imported from China, which makes it important to assure the public of the quality of these products. At this time, over sixty percent of FDA regulated products imported from China are medical devices and twenty percent are housewares, like food packaging."